A double-blind, placebo-control, randomized phase III study to evaluate the efficacy and safety of TAC-202 in patients with perennial allergic rhinitis

Taiho Pharmaceutical Co., Ltd.0 个研究点目标入组 750 人开始时间: 待定

试验速览

暂无简介。

研究类型: Interventional
干预模型: Double-blind, randomized, placebo-controlled, parallel-group, multicenter

•Subjects who have been diagnosed with perennial allergic rhinitis and who have had related symptoms for 2 years or longer.
•Subjects who showed positive in nasal provocation test with house dust disc.

•Subjects who previously developed anaphylaxis to antihistamine drugs, fexofenadine or ingredients of the investigational drug.
•Subjects with any of the following complications that may hinder efficacy evaluation
•Vasomotor rhinitis, - Eosinophilic rhinitis, - Drug-induced rhinitis,
•Viral conjunctivitis, - Otitis media,
•Others (acute/chronic rhinitis, hypertrophic rhinitis, sinusitis, nasal polyps, repetitive nasal hemorrhage, treatment-requiring nasal septal deviation, etc.)

Mean change in total nasal symptom scores (TNSS)

Scores for rhinorrhea, sneezing, nasal congestion and nasal itching

Symptoms score by subjects

Using the patient's diary card

发起方